Reply to: The Role of Risk-Reducing Bilateral Mastectomy in
 BRCA1
 and
 BRCA2
 Pathogenic Variant Carriers

Ashu Gandhi; Sacha J. Howell; D. Gareth Evans

doi:10.1200/jco-26-01190

Reply to: The Role of Risk-Reducing Bilateral Mastectomy in BRCA1 and BRCA2 Pathogenic Variant Carriers

A Ashu Gandhi (Ashu Gandhi, MD, Division of Cancer Sciences, Faculty of Biology, Medicine & Health, University of Manchester, Manchester, United Kingdom, Manchester University Hospitals, Manchester, United Kingdom, Manchester Academic Health Sciences Centre & Manchester Breast Centre, University of Manchester, Manchester, United Kingdom; Sacha J. Howell, PhD, Division of Cancer Sciences, Faculty of Biology, Medicine & Health, University of Manchester, Manchester, United Kingdom, Manchester University Hospitals, Manchester, United Kingdom, Manchester Academic Health Sciences Centre & Manchester Breast Centre, University of Manchester, Manchester, United Kingdom, Christie Hospital NHS Foundation Trust, Manchester, United Kingdom; and D. Gareth Evans, MD, Manchester University Hospitals, Manchester, United Kingdom, Manchester Academic Health Sciences Centre & Manchester Breast Centre, University of Manchester, Manchester, United Kingdom, Manchester Centre for Genomic Medicine, Manchester University Hospi...) S Sacha J. Howell D D. Gareth Evans

View Original

APA MLA Chicago BibTeX RIS

Article Details

Journal Journal of Clinical Oncology

Volume / Issue Vol. 1, Issue 1

Published July 09, 2026

DOI 10.1200/jco-26-01190

ISSN 0732-183X

Publisher Lippincott Williams & Wilkins

Journal Info

Journal of Clinical Oncology

Lippincott Williams & Wilkins

ISSN: 0732-183X Health Sciences

Authors (3)

A

Ashu Gandhi

Ashu Gandhi, MD, Division of Cancer Sciences, Faculty of Biology, Medicine & Health, University of Manchester, Manchester, United Kingdom, Manchester University Hospitals, Manchester, United Kingdom, Manchester Academic Health Sciences Centre & Manchester Breast Centre, University of Manchester, Manchester, United Kingdom; Sacha J. Howell, PhD, Division of Cancer Sciences, Faculty of Biology, Medicine & Health, University of Manchester, Manchester, United Kingdom, Manchester University Hospitals, Manchester, United Kingdom, Manchester Academic Health Sciences Centre & Manchester Breast Centre, University of Manchester, Manchester, United Kingdom, Christie Hospital NHS Foundation Trust, Manchester, United Kingdom; and D. Gareth Evans, MD, Manchester University Hospitals, Manchester, United Kingdom, Manchester Academic Health Sciences Centre & Manchester Breast Centre, University of Manchester, Manchester, United Kingdom, Manchester Centre for Genomic Medicine, Manchester University Hospi...

S

Sacha J. Howell

D

D. Gareth Evans

Reply to: The Role of Risk-Reducing Bilateral Mastectomy in <i>BRCA1</i> and <i>BRCA2</i> Pathogenic Variant Carriers

Article Details

Journal Info

Authors (3)

Related Articles from this Journal

Prostate-Specific Membrane Antigen Positron Emission Tomography and Radiometabolic Therapies in Metastatic Castration-Resistant Prostate Cancer

Allogeneic CD70-Targeted Chimeric Antigen Receptor T-Cell Therapy for Advanced Renal Cell Carcinoma: Results From the Phase I TRAVERSE Trial

Adjuvant Carboplatin for Early-Stage, Triple-Negative Breast Cancer: Taxane and Patient Selection

Erratum: All-Oral Combination of Revumenib, Decitabine, and Venetoclax for Relapsed or Refractory AML (SAVE)

Reply to: Prostate-Specific Membrane Antigen Positron Emission Tomography and Radiometabolic Therapies in Metastatic Castration-Resistant Prostate Cancer